Standard Biotools Inc. · NASDAQ:LAB
Standard Biotools — Fluidigm — Investor Presentation (January 2017)
24 slides from Standard Biotools's investor presentation, Jan 9, 2017
Slide 1: Fluidigm Investor Presentation January 2017
Fluidigm Investor Presentation January 2017 ® Exhibit 99.2
Slide 2: Use of Forward-Looking Statements
Use of Forward-Looking Statements This presentation contains, and accompanying oral statements may contain, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding potential applications for, and features an
Slide 3: Use of Non-GAAP Financial Information
Use of Non-GAAP Financial Information In this presentation, Fluidigm has presented certain financial information in accordance with GAAP and also on a non-GAAP basis for the first nine months of 2016 and 2015. Management believes that non-GAAP financial measures, taken in conjunction with GAAP finan
Slide 4: Fluidigm: An innovative leader in cell and tissue analysis
Fluidigm An innovative leader in cell and tissue analysis for translational and clinical research Mass Cytometry Genomics January 9, 2017
Slide 5: Empowering translational, clinical and pharmaceutical research
Empowering translational, clinical and pharmaceutical research Obtain comprehensive cellular profiles from blood, tissues, and tumors in human and animal model systems. Discover rare cell populations and biomarkers that inform disease progression and therapeutic development. Affordably scale next-ge
Slide 6: Mass cytometry advantages
Mass cytometry advantages Unlocking new insights January 9, 2017 Deeply profile 40+ parameters across millions of cells with little to no signal overlap, all from a single tube. Flexible Maxpar® panels can be easily customized. Maximize results from precious samples. Proven technology, referenced by
Slide 7: Mass cytometry workflow
Mass cytometry workflow Stain cells using Fluidigm validated protocols and buffers 3 Acquire high-parameter data for millions of cells with the Helios™ mass cytometer 4 Analyze data using cloud-based Cytobank Design panels using Maxpar® antibodies & reagents or use pre-designed Maxpar panels 1 2 Jan
Slide 8: Imaging mass cytometry workflow
Imaging mass cytometry workflow Stain cells and tissues on slides using Fluidigm validated protocols and buffers 3 Image high-parameter data for millions of cells with the Imaging Mass Cytometry System 4 Analyze data using cloud-based MiCAT freeware. Design panels using Maxpar® antibodies & reagents
Slide 9: Immune monitoring
Immune monitoring Comprehensive immune cell profiling Monitor the effects of immunotherapies and vaccine strategies in cancer Seeking the ability to deeply profile cell surface, intracellular and phospho-protein markers in immune cell populations. Require panel flexibility, to customize based on eac
Slide 10: Cancer biomarker development
Cancer biomarker development Identification of multi-biomarker signatures in spatial context Interrogate tumor sections and cell smears across multiple protein biomarkers to develop prognostic and diagnostic biomarker signatures. Visualize cancer and immune cell biomarkers in spatial context. Ensure
Slide 11: Genomics: the power of microfluidics
Genomics: the power of microfluidics Greater cost-effectiveness with reagent miniaturization Scalable sample throughput without changing technologies Flexible panel design allowing additional markers to be easily added over time. Maximize results from precious samples Trusted performance similar to
Slide 12: Providing efficient NGS library prep and qPCR workflows
Providing efficient NGS library prep and qPCR workflows 1 3 qPCR Biomark™ HD 2 qPCR assay prep Juno™ system 2 NGS library prep Juno™ or Access Array™ 3 NGS Illumina systems qPCR DNA/RNA from cells & tissues: Other industry providers Single cell isolation: C1™ or Polaris™ NGS January 9, 2017
Slide 13: Clinical Research laboratories
Clinical Research laboratories Scalable and cost efficient genomic analysis Routine screening of somatic and inherited mutations. Lower cost per sample, reduced hands on time to maximize profitability Access to proven pre-designed clinical research panels and flexible options to customize over time.
Slide 14: Human atlas initiative
Human atlas initiative Development of a comprehensive atlas at single cell resolution Develop a comprehensive cell atlas of the human cells and tissues. Large scale screening to identify unique cell populations. Deep profiling of defined cell populations to bring greater meaning in health and diseas
Slide 15: A complete view: oncology research
A complete view: oncology research Identification of tumor and blood associated biomarker signatures Somatic variant detection Juno™ NGS library prep Immuno-oncology gene expression Biomark™ HD Tissue biomarker signatures Imaging mass cytometry (in development) Identify & monitor immune signatures H
Slide 16: Attractive growing markets
Attractive growing markets Genomics Genomics market driven by conversion to next-generation sequencing Fluidigm (incl. Biomark, EP1, & Juno) competitive in mid-plex market; provide low cost, efficient, accurate solution for limited and low quality samples Sources: Fluidigm internal estimates, DeciBi
Slide 17: Vision and strategy implementation
Vision Single-cell Pioneer Translational Biology Partner Empowering Healthcare Insight Themes “What if” focus Emphasize general purpose instrument sales Breakthrough innovation R&D approach “So what” focus Build application and workflow solutions Balance R&D investment with sustaining and derivative
Slide 18: Preliminary revenue for Q4 & FY 2016
Preliminary revenue for Q4 & FY 2016 *These financial results are preliminary and subject to completion of Fluidigm’s financial statements for the year ended December 31, 2016, and the audit of those financial statements by its independent registered public accounting firm **Year-over-year and quart
Slide 19: Appendix
Appendix
Slide 20: First nine months 2016 revenue profile
First nine months 2016 revenue profile Revenue by geography Revenue by category Revenue by customer January 9, 2017
Slide 21: Revenue and product margins
*2014 total revenue includes proteomics sales of $20.7m. **Reconciliation of these non-GAAP measures to GAAP product margins is provided at the end of this presentation. Revenue and product margins Revenue (millions of dollars)* Product margins (%)** Non-GAAP GAAP January 9, 2017
Slide 22: Reconciliation of GAAP to non-GAAP net loss
Reconciliation of GAAP to non-GAAP net loss January 9, 2017 (a) represents amortization of developed technology in connection with the DVS acquisition (b) represents interest expense on Senior Convertible Notes (c) represents the tax impact on the purchase of intangible assets in connection with the
Slide 23: Reconciliation of GAAP to non-GAAP product margins
Reconciliation of GAAP to non-GAAP product margins January 9, 2017 (a) represents amortization of developed technology in connection with the DVS acquisition (d) represents expense associated with cost of product revenue
Slide 24: Trademarks
©2017 Fluidigm Corporation. All rights reserved. Fluidigm, the Fluidigm logo, Helios, CyTOF, Maxpar, Juno, Biomark, C1, Polaris, and Callisto are trademarks or registered trademarks of Fluidigm Corporation in the United States and/or other countries. All other trademarks are property of their respec